Insmed (INSM) Stock Price Up 0%

Insmed Incorporated (NASDAQ:INSM) shares traded up 0% on Thursday . The stock traded as high as $30.89 and last traded at $30.70. 848,067 shares changed hands during trading, an increase of 21% from the average session volume of 699,407 shares. The stock had previously closed at $30.70.

Several research analysts recently weighed in on the stock. BidaskClub upgraded shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Insmed in a report on Wednesday, September 6th. Evercore ISI boosted their price target on shares of Insmed from $28.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. Robert W. Baird restated a “positive” rating and set a $32.00 price target (up from $23.00) on shares of Insmed in a report on Wednesday, September 6th. Finally, Stifel Nicolaus restated a “buy” rating and set a $43.00 price target (up from $27.00) on shares of Insmed in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $34.50.

The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21.

In other Insmed news, Director Donald J. Hayden, Jr. sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total value of $487,500.00. Following the transaction, the director now directly owns 71,131 shares in the company, valued at $2,311,757.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.03% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Wisconsin Investment Board bought a new stake in shares of Insmed in the second quarter valued at approximately $789,000. Pictet Asset Management Ltd. raised its position in shares of Insmed by 5.6% in the third quarter. Pictet Asset Management Ltd. now owns 138,543 shares of the biopharmaceutical company’s stock valued at $4,324,000 after purchasing an additional 7,400 shares during the period. Vanguard Group Inc. raised its position in shares of Insmed by 1.2% in the second quarter. Vanguard Group Inc. now owns 3,827,881 shares of the biopharmaceutical company’s stock valued at $65,687,000 after purchasing an additional 46,398 shares during the period. Teachers Advisors LLC raised its position in shares of Insmed by 4.9% in the second quarter. Teachers Advisors LLC now owns 193,807 shares of the biopharmaceutical company’s stock valued at $3,326,000 after purchasing an additional 9,014 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Insmed in the third quarter valued at approximately $256,000. Hedge funds and other institutional investors own 95.28% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.com-unik.info/2017/12/23/insmed-insm-stock-price-up-0.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit